Michael Gold to Risk Assessment
This is a "connection" page, showing publications Michael Gold has written about Risk Assessment.
Connection Strength
1.989
-
Outcomes of subcutaneous implantable cardioverter-defibrillator in dialysis patients: Results from the S-ICD post-approval study. Heart Rhythm. 2020 09; 17(9):1566-1574.
Score: 0.437
-
Dynamic changes of T-wave alternans: does it predict short-term arrhythmia vulnerability? J Cardiovasc Electrophysiol. 2007 May; 18(5):518-9.
Score: 0.176
-
Predicting complete heart block after alcohol septal ablation for hypertrophic cardiomyopathy using a risk stratification model and clinical tool. Catheter Cardiovasc Interv. 2021 08 01; 98(2):393-400.
Score: 0.115
-
Use of antibiotic envelopes to prevent cardiac implantable electronic device infections: A meta-analysis. J Cardiovasc Electrophysiol. 2018 04; 29(4):609-615.
Score: 0.094
-
Treatment of Subclinical Atrial Fibrillation: Does One Plus One Always Equal Two? Circulation. 2018 01 16; 137(3):217-218.
Score: 0.093
-
The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis. Eur J Heart Fail. 2018 04; 20(4):780-791.
Score: 0.093
-
Utility of PET/CT to Evaluate Retroperitoneal Lymph Node Metastasis in High-Risk Endometrial Cancer: Results of ACRIN 6671/GOG 0233 Trial. Radiology. 2017 05; 283(2):450-459.
Score: 0.087
-
Newer Indications for ICD and CRT. Cardiol Clin. 2014 May; 32(2):181-90.
Score: 0.071
-
Cardiac resynchronization therapy in mild heart failure: a review of the REVERSE and MADIT-CRT trials. Curr Cardiol Rep. 2010 Sep; 12(5):367-73.
Score: 0.056
-
Risk stratification of ventricular arrhythmias in patients with systolic heart failure. Curr Opin Cardiol. 2010 May; 25(3):268-75.
Score: 0.055
-
Role of cardiac resynchronization therapy in asymptomatic and mildly symptomatic heart failure. Curr Heart Fail Rep. 2009 Mar; 6(1):44-8.
Score: 0.050
-
Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008 Nov 18; 52(21):1718-23.
Score: 0.049
-
Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy. Circulation. 2008 Nov 11; 118(20):2022-8.
Score: 0.049
-
Preventing tomorrow's sudden cardiac death today: part I: Current data on risk stratification for sudden cardiac death. Am Heart J. 2007 Jun; 153(6):941-50.
Score: 0.045
-
Preventing tomorrow's sudden cardiac death today: part II: Translating sudden cardiac death risk assessment strategies into practice and policy. Am Heart J. 2007 Jun; 153(6):951-9.
Score: 0.045
-
Sudden cardiac death: the role of risk stratification. Am Heart J. 2007 Apr; 153(4 Suppl):25-33.
Score: 0.044
-
Iatrogenic ventricular dyssynchrony: a preventable cause of heart failure with right ventricular pacing? Heart Rhythm. 2005 Mar; 2(3):252-3.
Score: 0.038
-
Treatment of pancreatic pseudoaneurysm with percutaneous transabdominal thrombin injection. J Vasc Surg. 2003 Sep; 38(3):600-2.
Score: 0.034
-
T wave alternans for ventricular arrhythmia risk stratification. Minerva Cardioangiol. 2003 Feb; 51(1):15-9.
Score: 0.033
-
Estimated incidence of previously undetected atrial fibrillation on a 14-day continuous electrocardiographic monitor and associated risk of stroke. Europace. 2022 07 21; 24(7):1058-1064.
Score: 0.032
-
T wave alternans: predictor of arrhythmic events? J Cardiovasc Electrophysiol. 2002 May; 13(5):513-4.
Score: 0.031
-
Using the years-of-healthy-life measure to calculate QALYs. Am J Prev Med. 2001 Jan; 20(1):35-9.
Score: 0.029
-
A comparison of T-wave alternans, signal averaged electrocardiography and programmed ventricular stimulation for arrhythmia risk stratification. J Am Coll Cardiol. 2000 Dec; 36(7):2247-53.
Score: 0.028
-
Active-Fixation Atrial Leads and the Risk of Atrial Fibrillation: Insights From ASSERT. Circ Arrhythm Electrophysiol. 2020 09; 13(9):e008655.
Score: 0.028
-
Short term escape rhythm characteristics after radiofrequency ablation of the atrioventricular junction. J Interv Card Electrophysiol. 2000 Apr; 4(1):301-5.
Score: 0.027
-
Real-world outcomes of ventricular tachycardia catheter ablation with versus without intracardiac echocardiography. J Cardiovasc Electrophysiol. 2020 02; 31(2):417-422.
Score: 0.027
-
Noninvasive tissue adhesive for cardiac implantable electronic device pocket closure: the TAPE pilot study. J Interv Card Electrophysiol. 2019 Mar; 54(2):171-176.
Score: 0.025
-
Precision Medicine for Cardiac Resynchronization: Predicting Quality of Life Benefits for Individual Patients-An Analysis From 5 Clinical Trials. Circ Heart Fail. 2017 Oct; 10(10).
Score: 0.023
-
The Role of I-123 Metaiodobenzylguanidine Imaging in Management of Patients With Heart Failure. Am J Cardiol. 2015 Oct 15; 116 Suppl 1:S1-9.
Score: 0.020
-
Relevance of electrical remodeling in human atrial fibrillation: results of the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial mechanisms of atrial fibrillation study. Circ Arrhythm Electrophysiol. 2012 Aug 01; 5(4):626-31.
Score: 0.016
-
Do Beta-blockers impact microvolt T-wave alternans testing in patients at risk for ventricular arrhythmias? A meta-analysis. J Cardiovasc Electrophysiol. 2010 Sep; 21(9):1009-14.
Score: 0.014
-
Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol. 2007 Sep 18; 50(12):1150-7.
Score: 0.011
-
Electrical storm presages nonsudden death: the antiarrhythmics versus implantable defibrillators (AVID) trial. Circulation. 2001 Apr 24; 103(16):2066-71.
Score: 0.007
-
The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996 Oct 09; 276(14):1172-7.
Score: 0.005